RxDoctor Payments Data

Conrad Rios

Family · Chowchilla, CANPI 1326037771

Payments from drug & device makers

$8,974in general payments, 2019–2025

Across 86 payments — averaging $104.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$997
  • Boehringer Ingelheim$958
  • AstraZeneca$895
  • Phathom Pharmaceuticals, Inc.$625
  • Amgen$501
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$409
  • plus $5K from 29 others

What the payments were for

  • Food & beverage$8,974100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,974 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$31,894
OzempicSemaglutide19$27,353
JanuviaSitagliptin Phosphate28$23,593
JardianceEmpagliflozin27$20,115
XareltoRivaroxaban17$18,456
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,605
RybelsusSemaglutide11$14,517
VascepaIcosapent Ethyl11$3,844
Albuterol Sulfate HfaAlbuterol Sulfate92$2,668
Levothyroxine Sodium187$2,377
Atorvastatin Calcium231$1,882
Duloxetine Hcl38$1,776
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$1,627
Gabapentin137$1,501
Lisinopril192$1,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$997$41,87030 claims
Boehringer IngelheimJardiance$958$20,11527 claims
GSKTrelegy Ellipta$36$14,60520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Chowchilla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →